Bifidobacterium infantis
Research reviewed: Up until 03/2026
Bifidobacterium infantis (Bifidobacterium longum subsp. infantis) is a dietary supplement with 20 published peer-reviewed studies involving 704 participants, researched for IBS Symptom Relief, Infant Microbiome, Anti-inflammatory Effects and 2 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
IBS Symptom Relief
ModerateInfant Microbiome
ModerateAnti-inflammatory Effects
ModerateClinical trials
ModerateSystematic reviews
WeakResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
IBS Symptom Relief
To evaluate B. infantis 35624 for IBS symptom relief.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate B. infantis 35624 for IBS symptom relief.
Dose
10^8 CFU/day
Participants
77 IBS patients (all subtypes)
Duration
8 weeks
Results
B. infantis 35624 significantly reduced abdominal pain, bloating, and bowel dysfunction compared to placebo. Normalized IL-10/IL-12 ratio indicating anti-inflammatory activity.
How They Measured It
IBS symptom composite score, individual symptoms, cytokine ratios
To determine optimal dose of B. infantis 35624 for IBS across all subtypes.
Study Type
Large-scale dose-ranging, double-blind, placebo-controlled
Purpose
To determine optimal dose of B. infantis 35624 for IBS across all subtypes.
Dose
10^6, 10^8, 10^10 CFU/day
Participants
362 female IBS patients
Duration
4 weeks
Results
10^8 CFU/day was the most effective dose, significantly improving all IBS symptoms. Both lower and higher doses were less effective.
How They Measured It
IBS-SSS, adequate relief, individual symptom scores
To assess long-term efficacy and safety of B. infantis 35624 for IBS.
Study Type
Open-label study
Purpose
To assess long-term efficacy and safety of B. infantis 35624 for IBS.
Dose
10^8 CFU/day
Participants
26 IBS patients from prior RCT
Duration
6 months
Results
Sustained improvement in IBS symptoms over 6 months with continued B. infantis supplementation. No adverse effects reported.
How They Measured It
IBS symptom scores, quality of life, safety monitoring
Infant Microbiome
To evaluate B. infantis EVC001 on gut colonization and microbiome in breastfed infants.
Study Type
Randomised controlled trial
Purpose
To evaluate B. infantis EVC001 on gut colonization and microbiome in breastfed infants.
Dose
8 × 10^9 CFU/day
Participants
68 breastfed term infants
Duration
60 days supplementation + 30 days follow-up
Results
B. infantis EVC001 colonized at high levels (>80% of fecal microbiome), efficiently consumed HMOs, lowered fecal pH, and reduced potential pathogens.
How They Measured It
Fecal B. infantis abundance, HMO utilization, fecal pH
To assess B. infantis EVC001 effects on intestinal inflammation and immune development in infants.
Study Type
Randomised, controlled
Purpose
To assess B. infantis EVC001 effects on intestinal inflammation and immune development in infants.
Dose
8 × 10^9 CFU/day
Participants
44 breastfed infants
Duration
60 days
Results
B. infantis EVC001 significantly reduced intestinal inflammation markers (fecal calprotectin) and promoted anti-inflammatory T-cell responses.
How They Measured It
Fecal calprotectin, cytokine profiles, immune cell phenotyping
Anti-inflammatory Effects
To evaluate B. infantis 35624 on systemic inflammatory markers.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate B. infantis 35624 on systemic inflammatory markers.
Dose
10^10 CFU/day
Participants
22 patients with psoriasis, 16 with chronic fatigue syndrome, 18 with ulcerative colitis
Duration
6-8 weeks
Results
B. infantis 35624 significantly reduced plasma CRP and TNF-alpha levels across all three inflammatory conditions. Enhanced IL-10 secretion from PBMCs.
How They Measured It
CRP, TNF-alpha, IL-6 levels; cytokine profiles from PBMCs
To assess anti-inflammatory effects of B. infantis in ulcerative colitis.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess anti-inflammatory effects of B. infantis in ulcerative colitis.
Dose
10^9 CFU/day
Participants
48 patients with mild-moderate ulcerative colitis
Duration
8 weeks
Results
B. infantis supplementation showed improvement in clinical activity scores and modest reduction in fecal calprotectin. Not statistically significant for endoscopic scores.
How They Measured It
Clinical Activity Index, endoscopic scores, fecal calprotectin
Clinical trials
To investigate the effects of Bifidobacterium infantis in effects of kefir on symptoms, sleep, and gut microbiota in children with adhd: a randomised controlled trial.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Bifidobacterium infantis in effects of kefir on symptoms, sleep, and gut microbiota in children with adhd: a randomised controlled trial.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
Evidence indicates the gut microbiome may be altered in ADHD, suggesting that targeting gut bacteria could alleviate symptoms. This study examined the effects of kefir supplementation on ADHD symptoms, sleep, attention, and gut microbiome composition in children diagnosed with ADHD.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in effect of multispecies probiotics on autism symptoms: protocol for a randomized controlled trial (probaut).
Study Type
Clinical trial
Purpose
To investigate the effects of Bifidobacterium infantis in effect of multispecies probiotics on autism symptoms: protocol for a randomized controlled trial (probaut).
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
n worldwide, negatively impacting the daily functioning and quality of life of patients and their families. New therapeutic approaches for ASD are being investigated. Probiotics have shown promise in modulating gut microbiota and ameliorating ASD symptoms. We aim to evaluate the impact of a 12-week multispecies probiotic supplementation on the severity of core autism symptoms in children with ASD.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in effects of a live versus heat-inactivated probiotic bifidobacterium spp in preterm infants: a randomised clinical trial.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Bifidobacterium infantis in effects of a live versus heat-inactivated probiotic bifidobacterium spp in preterm infants: a randomised clinical trial.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
32 weeks
Results
Heat-inactivated probiotics (HPs) may provide an effective alternative to live probiotics (P) by avoiding their risks (eg, probiotic sepsis) while retaining the benefits. We assessed the safety and efficacy of a HP in very preterm (VP: gestation <32 weeks) infants.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in safety and tolerance of bifidobacterium longum subsp. infantis ylgb-1496 in toddlers with respiratory symptoms.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Bifidobacterium infantis in safety and tolerance of bifidobacterium longum subsp. infantis ylgb-1496 in toddlers with respiratory symptoms.
Dose
1496 g
Participants
Participants not specified
Duration
Duration not specified
Results
: B. infantis YLGB-1496 demonstrated excellent safety and tolerability in toddlers and effectively reduced the gastrointestinal discomfort associated with respiratory illnesses.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in clinical benefits of bifidobacterium infantis ylgb-1496 in modulating gut microbiota and immunity in young children.
Study Type
Clinical trial
Purpose
To investigate the effects of Bifidobacterium infantis in clinical benefits of bifidobacterium infantis ylgb-1496 in modulating gut microbiota and immunity in young children.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
arly-life gut microbiota is critical for immune development and long-term health, and plays an essential role in the digestion and metabolism of dietary components, including human milk oligosaccharides (HMOs). Probiotic supplementation is a promising strategy to modulate this ecosystem and prevent common childhood infectious illnesses, though strain-specific effects require further investigation.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in bifidobacterium and lactobacillus probiotics and gut dysbiosis in preterm infants: the primal randomized clinical trial.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Bifidobacterium infantis in bifidobacterium and lactobacillus probiotics and gut dysbiosis in preterm infants: the primal randomized clinical trial.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
The effects of probiotic interventions on colonization with resistant bacteria and early microbiome development in preterm infants remain to be clarified.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in pre-sleep casein ingestion with probiotic strains improves anaerobic power and lower-body-specific strength and power performance in soccer players.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Bifidobacterium infantis in pre-sleep casein ingestion with probiotic strains improves anaerobic power and lower-body-specific strength and power performance in soccer players.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
ers have recently focused on the relationship between probiotic consumption and improved gut microbiota function, enhanced digestion, increased nutrient absorption, and enhanced sports performance. Therefore, the present study investigated the effects of pre-sleep casein intake, coupled with probiotic strains, on soccer players' anaerobic power, lower-body-specific strength, and power performance.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in therapeutic potential of bifidobacterium longum subsp. infantis b8762 on gut and respiratory health in infant.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Bifidobacterium infantis in therapeutic potential of bifidobacterium longum subsp. infantis b8762 on gut and respiratory health in infant.
Dose
10 CFU
Participants
57 participants
Duration
4 weeks
Results
tokine response, indicating modulation of the immune system. Genomic analysis showed that B8762 harbors various genes for the synthesis of proteins and vitamins crucial for the gut health of children. Both the clinical and genomic findings suggested that B8762 offered a therapeutic effect on gut and respiratory health in children, highlighting its potential in managing common pediatric infections.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in feasibility, safety, and impact of the probiotics lactiplantibacillus plantarum and bifidobacterium longum subspecies infantis in papua new guinean in
Study Type
Clinical trial
Purpose
To investigate the effects of Bifidobacterium infantis in feasibility, safety, and impact of the probiotics lactiplantibacillus plantarum and bifidobacterium longum subspecies infantis in papua new guinean in
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
Childhood mortality in low- or middle-income countries (LMICs) remains a major public health concern, with infections being a leading cause of infant death. Probiotics have shown promise in reducing infection-related morbidity and mortality in preterm infants, but their use in newborns born at or near term in LMICs requires further investigation.
How They Measured It
See study for outcome measures
Systematic reviews
To investigate the effects of Bifidobacterium infantis in probiotics in term infants: clinical impact of infant-type bifidobacteria: a systematic review and meta-analyses.
Study Type
Systematic review and meta-analysis
Purpose
To investigate the effects of Bifidobacterium infantis in probiotics in term infants: clinical impact of infant-type bifidobacteria: a systematic review and meta-analyses.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
iratory tract infections. However, the evidence is limited by study heterogeneity and a lack of long-term follow-up data. Further high-quality randomized controlled trials with larger sample sizes and standardized outcome measures are needed to clarify both short- and long-term effects of ITB probiotic administration in neonates and infants. This trial was registered at PROSPERO as CRD42024507608.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in probability of vertical hiv transmission: a systematic review and meta-regression.
Study Type
Systematic review
Purpose
To investigate the effects of Bifidobacterium infantis in probability of vertical hiv transmission: a systematic review and meta-regression.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
stimating paediatric HIV infections with the Joint United Nations Programme on HIV/AIDS supported Spectrum AIDS Impact Module (Spectrum-AIM). Recent innovations in antiretroviral therapy (ART) service delivery models and first-line regimens aimed to reduce VT probabilities. We conducted a systematic review and meta-analysis to estimate VT probabilities by maternal immunologic and treatment status.
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in the effectiveness of probiotics as an adjunct therapy in patients under mechanical ventilation: an umbrella systematic review and meta-analysis.
Study Type
Systematic review and meta-analysis
Purpose
To investigate the effects of Bifidobacterium infantis in the effectiveness of probiotics as an adjunct therapy in patients under mechanical ventilation: an umbrella systematic review and meta-analysis.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
, B. salivarius , Pediococcus pentosaceus , Lactococcus raffinolactis , B. infantis , B. bifidum , Streptococcus thermophilus , Ligilactobacillus salivarius , L. lactis , B. lactis , Saccharomyces boulardii , L. rhamnosus GG, L. johnsonii , L. casei , S. faecalis , Clostridium butyricum , Bacillus mesentericus , L. sporogenes , S. boulardii , L. paracasei , B. subtilis , and Enterococcus faecium .
How They Measured It
See study for outcome measures
To investigate the effects of Bifidobacterium infantis in probability of vertical hiv transmission: a systematic review and meta-regression.
Study Type
Systematic review and meta-analysis
Purpose
To investigate the effects of Bifidobacterium infantis in probability of vertical hiv transmission: a systematic review and meta-regression.
Dose
Bifidobacterium infantis (dose not specified)
Participants
Participants not specified
Duration
Duration not specified
Results
arly-life gut microbiota is critical for immune development and long-term health, and plays an essential role in the digestion and metabolism of dietary components, including human milk oligosaccharides (HMOs). Probiotic supplementation is a promising strategy to modulate this ecosystem and prevent common childhood infectious illnesses, though strain-specific effects require further investigation.
How They Measured It
See study for outcome measures
Frequently Asked Questions
Common questions about Bifidobacterium infantis research
There are currently 20 peer-reviewed studies on Bifidobacterium infantis (Bifidobacterium longum subsp. infantis), involving 704 total participants. Research covers IBS Symptom Relief, Infant Microbiome, Anti-inflammatory Effects and 2 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (16 human studies), and reported outcomes.
Bifidobacterium infantis has been researched for: IBS Symptom Relief, Infant Microbiome, Anti-inflammatory Effects, Clinical trials, Systematic reviews. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 16 out of 20 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
